Publikationen in Zusammenarbeit mit Forschern von Hospital Clínico San Carlos de Madrid (135)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  2. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  3. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  4. Clinical impact of remote heart failure management using the multiparameter ICD HeartLogic alert

    Revista Espanola de Cardiologia

  5. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  6. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  7. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary

  8. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  9. Increased Severity of Mycoplasma pneumoniae Infections in Spanish Children

    Pediatric Infectious Disease Journal

  10. Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study

    Actas Urologicas Espanolas, Vol. 48, Núm. 3, pp. 228-237

  11. Pulmonary function and bronchopulmonary dysplasia classification: insights from the Spanish Registry

    European Journal of Pediatrics, Vol. 183, Núm. 9, pp. 3757-3766

  12. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)

    Surgical Oncology, Vol. 52

  13. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  2. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  3. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

    Seminars in Arthritis and Rheumatism, Vol. 58

  4. Análisis coste-utilidad del modelo de unidad de terapia intravítrea (UTI) frente a la administración tradicional de terapia intravítrea

    Archivos de la Sociedad Española de Oftalmologia, Vol. 98, Núm. 11, pp. 619-626

  5. Consumption of health resources in older people with differentiated thyroid carcinoma: a multicenter analysis

    Endocrine, Vol. 81, Núm. 3, pp. 521-531

  6. Correction: Three-year survival and distribution of lymph node metastases in gastric cancer following neoadjuvant chemotherapy: results from a European randomized clinical trial (Surgical Endoscopy, (2023), 37, 9, (7317-7324), 10.1007/s00464-023-10278-5)

    Surgical Endoscopy

  7. Impact of a delayed presentation to the emergency department for acute renal colic on biochemical and clinical outcomes

    Actas Urologicas Espanolas, Vol. 47, Núm. 1, pp. 41-46